Equities

Vistin Pharma ASA

Vistin Pharma ASA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NOK)25.00
  • Today's Change0.10 / 0.40%
  • Shares traded22.18k
  • 1 Year change+12.61%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of NOK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments261.4436
Total Receivables, Net607143
Total Inventory808343
Prepaid expenses2.813.1416
Other current assets, total------
Total current assets169159138
Property, plant & equipment, net220219167
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets----0.00
Total assets403407333
LIABILITIES
Accounts payable192621
Accrued expenses----20
Notes payable/short-term debt0450
Current portion long-term debt/capital leases511.07--
Other current liabilities, total0.00460.14
Total current liabilities6911841
Total long term debt000
Total debt51460
Deferred income tax------
Minority interest------
Other liabilities, total111616
Total liabilities8113457
SHAREHOLDERS EQUITY
Common stock444444
Additional paid-in capital207207207
Retained earnings (accumulated deficit)722225
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity323273276
Total liabilities & shareholders' equity403407333
Total common shares outstanding444444
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.